原发纵隔大B细胞淋巴瘤的治疗进展

Progress in Treatment of Primary Mediastinal Large B-cell Lymphoma

原发纵隔大B细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBCL)是来源于胸腺髓质B细胞的恶性肿瘤,属于弥漫大B细胞淋巴瘤的特殊亚型。由于发病率低,缺乏大样本前瞻性临床研究,目前PMBCL尚无统一的治疗方案,主要治疗方式包括化疗、放疗、自体干细胞移植及靶向治疗等。PMBCL具有特殊的分子生物学特征,这一特点为其特征性的治疗提供了重要参考。全文将主要就PMBCL的治疗进展作一综述。

Primary mediastinal large B-cell lymphoma(PMBCL),a special subtype of diffuse large B-cell lymphoma(DLBCL),is derived from thymic medullary B cells. Due to the low incidence and lack of large-scale prospective clinical studies,there is no consensus onthe treatment protocol for PMBCL. The main therapeutic methods of PMBCL include chemotherapy,radiotherapy,autologous stem cell transplantation and targeted therapy. PMBCL has special molecular biological features,which provides an important reference for its characteristic treatment. This article briefly introduces the current progress of PMBCL treatment.